Global Pathology Support is committed to providing peer reviews of incumbent immunotherapy treatments currently undergoing clinical and preclinical studies. Interleukins, chemokines, or other cell-based immunotherapies have the potential to be instrumental in combating cancer. Our pathology consultants can provide guidance in the field of immunohistochemistry.
Contributing to immunotherapy development with pathology services
Monoclonal antibody immunotherapy treatments such as those targeting HER2/neu can prove effective against breast cancer. To ensure such potentially life-saving treatments are thoroughly tested, we provide immunohistochemistry services as an essential preclinical safety assessment. Global Pathology Support's Dr. Robertus Thoolen has ample experience in peer reviewing carcinogenicity studies, ensuring the delivery of accurate pathology data. In sensitive preclinical assessments such as these, it is important for a consummate professional to corroborate results. In this manner, subsequent clinical trials can proceed as efficiently as possible. For some patients, the time gained may quite literally make the difference between life or death.
Better medicine through thorough research
We gladly provide the pathology services and consultancy that your immunotherapy research needs to succeed. Your company will benefit from our decades of pathology experience to deliver a product that your clients will be able to use safely and effectively. Call us today at +31 (0)70-314 24 04 to discover how Global Pathology Support can fulfil your research needs.